Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

I don’t believe it’s in response to MRC’s

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Mellowmood77 Member Profile
Member Level 
Followed By 26
Posts 532
Boards Moderated 0
Alias Born 04/30/19
160x600 placeholder
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascep... GlobeNewswire Inc. - 8/8/2019 4:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares GlobeNewswire Inc. - 7/29/2019 5:17:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2019 4:32:58 PM
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019 GlobeNewswire Inc. - 7/24/2019 6:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2019 5:01:04 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/18/2019 11:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 4:38:44 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 4:02:07 PM
Amarin Announces $400,000,000 Public Offering of American Depositary Shares GlobeNewswire Inc. - 7/17/2019 4:01:00 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:15:19 AM
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance GlobeNewswire Inc. - 7/2/2019 6:00:00 AM
Mellowmood77 Member Level  Thursday, 09/19/19 07:41:16 PM
Re: rafunrafun post# 215212
Post # of 219978 
I don’t believe it’s in response to MRC’s petition, especially since it more specifically talks about ANDA’s. But maybe MRC’s CP was the straw that broke the camel’s back. Who knows! But the AGENDA sure matches the concerns MRC’s CP detailed: efficacy.

Most likely the ADCOM will be bringing up detailed MA’s on how EPA works, meta analyses of other studies that also had LDL increases in placebo arms (uhhh Nissen’s EPANOVA?!), and other details that have yet been revealed (epa/aa levels etc).

I am not worried about ADCOM. The fact of the matter is this:

They might not be able to prove 100 percent that mineral oil didn’t inflate the results of the trial, BUT THEY CAN’T PROVE THAT IT DID EITHER.

Now given the safety profile of Vascepa (water might be more dangerous), what seems like the most logical thing to do if a DDI study is warranted? Approve it INTERIM, or force millions of patients that can possibly benefit from EPA to wait on a life saving drug?

Last ADCOM wasn’t unanimous. It was 7-2. Are we really to assume given the same voters, 3 of them wouldn’t approve after REDUCE-IT? Especially since almost all of them said they would like to wait for REDUCE-IT results?

SINCE then: ADA, NLA, ACC, AHA, MAYO, and others have given endorsements one way or another. Will they go against them?

No I am not worried even a little about the ADCOM. I’m 99% sure we will get approved. I’m just pissed we were forced into having one.

Robert Smith of the last ADCOM said something to the effect that it should be approved now given the safety profile so that patients might benefit from effects that aren’t currently understood. I gave the exact quote a while ago in another post.

What a smart human being.







Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist